What structural characteristics make AKAP11 a difficult target for standard quantitative immunoassays?

As a high-molecular-weight scaffolding protein (approx. 220 kDa), AKAP11 contains multiple protein-protein interaction domains that facilitate the assembly of signaling complexes involving PKA and GSK3$\beta$. In biological matrices, these endogenous complexes can sterically hinder antibody access to critical epitopes. Accurate quantification requires specialized lysis and stabilization buffers to ensure the dissociation of these complexes without compromising protein integrity.

How can analytical methods distinguish between full-length AKAP11 and clinically relevant truncating mutations?

The distinction relies on dual-epitope recognition strategies. By utilizing antibody pairs that target the N-terminal region and the C-terminal PKA-binding domain, assays can differentiate between the wild-type protein and truncated variants resulting from loss-of-function mutations. The absence of a C-terminal signal in the presence of an N-terminal signal is a definitive indicator of protein truncation.

What are the primary technical hurdles when detecting AKAP11 in cerebrospinal fluid (CSF)?

The primary challenge is the low physiological concentration of AKAP11 in the CSF compared to cellular lysates. Ultrasensitive detection requires high-affinity capture reagents and advanced signal amplification techniques to overcome the high signal-to-noise ratio typical of brain-derived biomarkers. Additionally, the presence of endogenous proteases in CSF necessitates immediate sample stabilization.

Can molecular interactions between AKAP11 and its signaling partners be monitored in vitro?

Yes, the dynamics of the AKAP11 scaffolding complex can be analyzed using proximity-based assays or competitive binding experiments. These techniques measure the affinity and stability of AKAP11's interaction with PKA regulatory subunits or GSK3$\beta$. Such analysis is vital for understanding how specific genetic variants or pharmacological agents disrupt the spatial compartmentalization of kinase signaling.

Why is AKAP11 particularly susceptible to degradation during sample processing?

AKAP11 contains several intrinsically disordered regions and multiple proteolytic cleavage sites that are highly sensitive to endogenous serine proteolysis. To maintain the native state of the protein for downstream analysis, strict adherence to cold-chain protocols and the utilization of broad-spectrum protease inhibitors during the initial homogenization and extraction phases are mandatory.

AKAP11 Analysis Service - Creative Biolabs

Are you currently facing challenges in identifying reliable biomarkers for bipolar disorder or schizophrenia, or struggling with the complexity of mapping protein kinase A (PKA) scaffolding networks in neural tissues? Our AKAP11 Analysis Services help you unlock the potential of this high-confidence risk gene through advanced high-affinity antibody development and ultrasensitive singleplex biomarker detection platforms. Accelerate your path from discovery to clinical application with Creative Biolabs' expert-driven solutions.

Introduction of AKAP11: A Critical Nexus in Neuropsychiatric Pathophysiology

A-Kinase Anchoring Protein 11 (AKAP11), also known as AKAP220, is a major member of the AKAP family that plays a pivotal role in compartmentalizing cyclic AMP-dependent protein kinase (PKA) and other signaling enzymes. Encoded by the AKAP11 gene on chromosome 13q14, this 220 kDa protein acts as a molecular scaffold, localizing PKA, protein phosphatase 1 (PP1), and GSK3β to specific subcellular sites. This spatial organization is fundamental for the fidelity of intracellular signaling, particularly in neurons and germ cells.

Recent large-scale exome sequencing studies have identified AKAP11 as a high-confidence risk gene for bipolar disorder and schizophrenia. Loss-of-function mutations in AKAP11 are strongly associated with increased susceptibility to these conditions, positioning it as a top-tier target for next-generation IVD development and therapeutic intervention. Beyond its role in the brain, AKAP11 is crucial for sperm motility and has been implicated in certain oncogenic pathways where signaling compartmentalization is disrupted. By providing reliable AKAP11 analysis, Creative Biolabs supports researchers in deciphering these complex signaling nodes and their clinical implications.

Application: Bridging Basic Science and Diagnostic Innovation

The versatility of AKAP11 as a biomarker and scaffolding protein makes it a focal point across several domains:

Service Highlights

Creative Biolabs offers an industry-leading suite of AKAP11 analysis services designed to overcome the hurdles of low endogenous expression and complex protein-protein interactions.

One-Stop Service

We provide a comprehensive, end-to-end service from initial project design and gene synthesis to high-quality antibody production and purification. This integrated approach simplifies your workflow and ensures data consistency.

High-Affinity Antibody Customization

We offer a wide selection of antibody formats, including full-length human IgGs and specialized formats like scFv and Fab, specifically validated for high-interference matrices.

Guaranteed High Purity and Low Endotoxin

Our advanced purification protocols ensure antibodies achieve a purity of up to 99%. This is a critical requirement for reliable in vitro diagnostic assays and cell-based functional studies.

Comprehensive QC Analysis

Based on Published Data, we perform extensive QC testing at every stage, including UV spectrophotometry, SDS-PAGE, ELISA, and HPLC. This ensures every batch meets the highest standards for specificity and stability.

Ultrasensitive Detection Platforms

Our singleplex biomarker analysis utilizes state-of-the-art platforms capable of detecting AKAP11 at femtogram levels, essential for clinical CSF samples.

Dedicated After-Sale Support

Our commitment extends beyond final delivery with dedicated after-sale support to ensure your custom antibodies and data perform optimally in your specific assay environment.

Service Workflow

01Initial Consultation and Project Design

The process begins with a detailed consultation where our scientific team discusses your research goals, target AKAP11 epitopes, and desired analytical outcomes. This collaborative phase establishes critical parameters and customizes the assay strategy to your specific project requirements.

02Sample Submission and Quality Control

Upon receipt, all biological materials undergo stringent quality control. We assess protein concentration and integrity using automated systems to ensure suitability for reliable, reproducible assay performance.

03Custom Reagent Development and Optimization

For AKAP11, which often requires specific orientations for PKA-binding site exposure, our experts undertake comprehensive assay optimization. This includes validating monoclonal antibodies against recombinant and endogenous AKAP11 to ensure peak performance and fit-for-purpose validation.

04Data Acquisition and Analysis

Samples are processed using our ultrasensitive immunoassays. High-quality data is meticulously acquired and interpreted using rigorous statistical methods to derive meaningful insights regarding AKAP11 concentration or interaction dynamics.

05Final Report and Consultation

The project concludes with a comprehensive final report detailing the methodology, raw data (SDS-PAGE/ELISA results), and expert interpretation. A follow-up consultation is provided to discuss findings and recommend subsequent research steps.

FAQs

Creative Biolabs is your premier partner for AKAP11 Analysis Services, providing the specialized expertise and cutting-edge technology required to navigate the complexities of PKA scaffolding and neuropsychiatric biomarker research. From high-affinity antibody production to ultrasensitive singleplex detection, we deliver the precision data your project demands.

Related Services:

Online Inquiry